Active	Status	Sponsor type	Region	Phase	Filter
8 Active 6 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
DiSilvestro, Paul
SOLO-1, NCT01844986 / 2013-001551-13: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. Seven-year follow-up from P3 SOLO-1 trial for ovarian cancer at ESMO 2022 Sep 2022 - Sep 2022: Seven-year follow-up from P3 SOLO-1 trial for ovarian cancer at ESMO 2022 Presentation of data from SOLO-1 trial in 1L ovarian cancer at SGO 2021 May 2021 - May 2021: Presentation of data from SOLO-1 trial in 1L ovarian cancer at SGO 2021 Presentation of data from SOLO-1 trial in 1L ovarian cancer at ESMO 2020 Sep 2020 - Sep 2020: Presentation of data from SOLO-1 trial in 1L ovarian cancer at ESMO 2020 5-year follow-up PFS data from SOLO-1 trial for ovarian cancer at ESMO 2020 Sep 2020 - Sep 2020: 5-year follow-up PFS data from SOLO-1 trial for ovarian cancer at ESMO 2020 Approved for 1L ovarian cancer based on SOLO-1 trial Jun 2019 - Jun 2019: Approved for 1L ovarian cancer based on SOLO-1 trial Submitted for 1L gBRCAm ovarian cancer (based on SOLO-1 trial) Nov 2018 - Nov 2018: Submitted for 1L gBRCAm ovarian cancer (based on SOLO-1 trial) SOLO-1 trial in BRCA+ 1L ovarian cancer at ESMO 2018 Oct 2018 - Oct 2018: SOLO-1 trial in BRCA+ 1L ovarian cancer at ESMO 2018 SOLO-1 trial in 1L maintenance BRCAm ovarian cancer Jul 2018 - Jul 2018: SOLO-1 trial in 1L maintenance BRCAm ovarian cancer SOLO-1 trial in 1L maintenance BRCAm ovarian cancer Feb 2018 - Feb 2018: SOLO-1 trial in 1L maintenance BRCAm ovarian cancer More	Active, not recruiting	3	450	Europe, Canada, Japan, US, RoW	Olaparib 300mg tablets	AstraZeneca, GOG Foundation, Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC	Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy	05/18	08/28
Bliss, Joseph M
No trials found
McGowan, Elisabeth
No trials found
Vohr, Betty R
No trials found